Searchable abstracts of presentations at key conferences in endocrinology

ea0059p173 | Obesity & metabolism | SFEBES2018

Fructose is metabolised by human subcutaneous adipocytes and can be used as a substrate for de novo lipogenesis

Pinnick Katherine , Cornfield Thomas , Green Charlotte , Hodson Leanne

Introduction: Excessive consumption of free sugars (glucose and fructose) is linked to an increased risk of developing chronic metabolic diseases. Current knowledge of fructose metabolism has focussed on the liver where it is implicated in impaired insulin sensitivity, increased fat accumulation and dyslipidaemia. The long-term effects of elevated fructose consumption on human health are poorly defined and fructose metabolism in subcutaneous adipose tissue, the largest human f...

ea0086oc5.5 | Metabolism, Obesity and Diabetes | SFEBES2022

Upregulation of hepatic de novo lipogenesis dissociates from changes in liver fat content and insulin sensitivity in healthy humans

Dearlove David , Parry Sion , Johnson Elspeth , Cornfield Thomas , Mozes Ferenc , Dyson Pam , Hodson Leanne

Introduction: Increased hepatic de novo lipogenesis (DNL) is often associated with greater intrahepatic triglyceride (IHTG) content and/or decreased insulin sensitivity; however, the contribution of DNL to each has not been fully elucidated. Therefore, the present work determined if increased DNL, achieved via adoption of an isocaloric high-sugar diet, resulted in concomitant increases in IHTG content and/or decreases in insulin sensitivity.Methods: Sixt...

ea0065oc1.2 | Metabolism and Obesity | SFEBES2019

Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism

Green Charlotte , Pramfalk Camilla , Charlton Catriona , Gunn Pippa , Cornfield Thomas , Pavalides Michael , Karpe Fredrik , Hodson Leanne

Background and Aim: Hepatic de novo lipogenesis (DNL) has been implicated in the development of non-alcoholic fatty liver disease (NAFLD). Supplementation with the omega-3 fatty acids (FA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) decreases intrahepatic triacylglycerol (IHTAG) and plasma TAG concentrations, which is suggested to be mediated through changes in hepatic DNL. We investigated the effects of omega-3 FA supplementation on intrahepatic DNL an...